


## Ectoin® Lozenges prove efficacy and high tolerability in clinical trial

### Results

- Ectoin® Lozenges significantly improve the pharyngitis symptoms pain on swallowing, tickle in the throat and hoarseness compared to first visit and compared to treatment with salt water gargling solution.
- Ectoin® Lozenges show significant superiority compared to Hyaluronic acid (HA)-containing lozenges (GeloRevoice®) in reducing redness of the mucosa in mouth and throat.
- After 7 days of treatment, the general condition of nearly 70 % of the patients using Ectoin® Lozenges was rated as "very good" by the physician. In comparison, only 48% of the patients using HA-containing lozenges and only 20% of the salt water group reached a "very good" condition after 7 days.
- The tolerability of Ectoin® Lozenges is significantly superior compared to HA-containing lozenges (physician's assessment).
- All patients treated with Ectoin® Lozenges were highly satisfied with the taste. In contrast, 40% of patients treated with HA-containing lozenges and 45% of the patients treated with salt water rated the taste of their product as unpleasant.

Figure: **Improvement (%) of pharyngitis symptoms after 7 days of treatment (physician's assessment)**



\* P < 0.05 versus salt water solution;

# P < 0.05 Ectoin® Lozenges versus HA-containing lozenges

## Study Fact I Ectoin® Lozenges prove efficacy and high tolerability in clinical trial

Table: Brief summary

<b>Study design</b>	Non-interventional, comparative, multicentre study
<b>Study population</b>	90 patients with acute viral pharyngitis <ul style="list-style-type: none"> <li>• 35 x Ectoin® Lozenges</li> <li>• 35 x HA-containing lozenges</li> <li>• 20 x salt water gargling solution</li> </ul>
<b>Treatment duration</b>	7 days; application according to instructions for use
<b>Assessment</b>	Physician assessment during initial and final visit; daily patient diaries
<b>Evaluated symptoms</b>	Pain on swallowing Tickle in the throat Hoarseness Dry mouth and throat Reddening of the oropharynx* Reddening of the larynx* Burning sensation in the throat Patient's general condition
<b>ClinicalTrials.gov Identifier</b>	NCT02669446

\* Symptoms were assessed during the site visits and documented in the medical documentation.



"We have chosen a very strong and effective comparative product for our Ectoin® Lozenges: GeloRevoice®, hyaluronic acid-containing lozenges. GeloRevoice® was one of the most successful OTC product launches in Germany during the last few years and has been established as an OTC bestseller. 2.74 Mio units have been sold during the last 12 months\*\* which resulted in a sales increase of 10.2%. The superiority of GeloRevoice® compared to other established OTC products (e.g. isla® moos, iceland moss-containing lozenges) was proven in various trials.

We are more than proud that the Ectoin® Lozenges showed superiority in very important parameters compared to the reference GeloRevoice®. Therefore, we are convinced that our innovative and effective Ectoin® Lozenges have the potential to further stir-up the market. Ectoin® Lozenges will be launched by a market leading pharmaceutical company in various European countries until end of this year."

*Dr. Andreas Bilstein (CSO bitop AG)*

\*\* MAT 06/2016, IMS

**Interested in a license? Please contact our business development team at [bd@bitop.de](mailto:bd@bitop.de)**